经由蛋白降解的调节在癌症生物学中已成为一个重复的主题,包括β-连环蛋白(β-catenin,细胞骨架蛋白)在内的很多癌蛋白因降解而成为被调控的靶标;蛋白酶体抑制因子作为抗癌药物已进入临床试验;但生物调控似乎并不那么简单。在近期出版的《欧洲分子生物学协会(EMBO)报告》中,Frank Staal及其同事证实调节β-连环蛋白活化的关 Regulation by proteolytic degradation has been a subject of repetition in cancer biology and many oncoproteins, including beta-catenin (cytoskeletal proteins), are regulated by degradation; proteasome inhibitory factor As an anti-cancer drug has entered clinical trials; but biological regulation does not seem so simple. In the recently published EMBO report, Frank Staal and colleagues confirm that the regulation of β-catenin activation